基于“肺–肠”轴与黏膜免疫防治IgA肾病
Prevention and Treatment of IgA Nephropathy Based on Lung-Intestinal Axis and Mucosal Immunity
DOI: 10.12677/acm.2025.151042, PDF,   
作者: 王 静：黑龙江中医药大学第一临床医学院，黑龙江 哈尔滨；金丽霞*：黑龙江中医药大学附属第四医院肾病科，黑龙江 哈尔滨；杜 琳：北京卫戍区海淀第三退休干部休养所，北京
关键词: “肺–肠”轴；黏膜免疫；IgA肾病；“Lung-Gut” Axis； Mucosal Immunity； IgA Nephropathy
摘要: IgA肾病(IgA nephropathy, IgAN)是多机制共同参与免疫介导的肾小球疾病，也是世界上最常见的原发性肾小球疾病，其病因及病理机制尚不明确，亦无特异性疗法，是国内外临床亟需解决的难题。现代医学研究表明IgA肾病与“肺–肠”轴和黏膜免疫关系密切，通过干预“肺–肠”轴传导对肾脏病产生调控作用，或可成为治疗IgA肾病的新靶点。且传统药物对IgA肾病的治疗经过多年发展已展现出其显著疗效及副作用小的优势。本文就目前“肺–肠”轴与黏膜免疫在IgAN发病机制中作用的研究进展进行归纳探讨，以期为未来从“肺–肠”轴与黏膜免疫角度寻找IgAN新的治疗靶点提供思路及为研究拓宽思路。
Abstract: IgA nephropathy (IgAN) is an immune-mediated glomerular disease that involves multiple mechanisms and is the most common primary glomerular disease in the world. The etiology and pathogenesis of IgA nephropathy are still unclear, and there is no specific therapy for IgA nephropathy, so it is a problem that needs to be solved urgently for both domestic and foreign clinics. Modern medical research has shown that IgA nephropathy is closely related to the “lung-intestinal” axis and mucosal immunity, and that interfering with the “lung-intestinal” conduction has a regulatory effect on renal disease, which may become a new target for the treatment of IgA nephropathy. Moreover, after years of development, traditional medicines for IgA nephropathy have demonstrated their remarkable efficacy and low side effects. In this paper, we summarize and discuss the current research progress on the role of lung-intestinal axis and mucosal immunity in the pathogenesis of IgAN, with a view to providing ideas and broadening the mindset for future research on finding new therapeutic targets for IgAN from the perspective of lung-intestinal axis and mucosal immunity.
文章引用：王静, 金丽霞, 杜琳. 基于“肺–肠”轴与黏膜免疫防治IgA肾病[J]. 临床医学进展, 2025, 15(1): 296-303. https://doi.org/10.12677/acm.2025.151042

参考文献

[1] Stamellou, E., Seikrit, C., Tang, S.C.W., Boor, P., Tesař, V., Floege, J., et al. (2023) IgA Nephropathy. Nature Reviews Disease Primers, 9, 67. [Google Scholar] [CrossRef] [PubMed]
[2] Pattrapornpisut, P., Avila-Casado, C. and Reich, H.N. (2021) IgA Nephropathy: Core Curriculum 2021. American Journal of Kidney Diseases, 78, 429-441. [Google Scholar] [CrossRef] [PubMed]
[3] Rajasekaran, A., Julian, B.A. and Rizk, D.V. (2021) IgA Nephropathy: An Interesting Autoimmune Kidney Disease. The American Journal of the Medical Sciences, 361, 176-194. [Google Scholar] [CrossRef] [PubMed]
[4] Zhang, H. and Barratt, J. (2021) Is IgA Nephropathy the Same Disease in Different Parts of the World? Seminars in Immunopathology, 43, 707-715. [Google Scholar] [CrossRef] [PubMed]
[5] Floege, J. (2024) IgA-Nephropathie. Die Urologie, 63, 103-111. [Google Scholar] [CrossRef] [PubMed]
[6] Brazdziute, E., Miglinas, M., Gruodyte, E., Priluckiene, J., Tamosaitis, A., Bumblyte, I.A., et al. (2015) Nationwide Renal Biopsy Data in Lithuania 1994-2012. International Urology and Nephrology, 47, 655-662. [Google Scholar] [CrossRef] [PubMed]
[7] Trimarchi, H., Barratt, J., Cattran, D.C., Cook, H.T., Coppo, R., Haas, M., et al. (2017) Oxford Classification of IgA Nephropathy 2016: An Update from the IgA Nephropathy Classification Working Group. Kidney International, 91, 1014-1021. [Google Scholar] [CrossRef] [PubMed]
[8] 张权, 凌春燕, 朱逸云, 等. 基于真实世界的中医药对IgA肾病肾功能保护作用研究[J]. 中国中医药信息杂志, 2021, 28(11): 103-107.
[9] Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A.B., Renfrow, M.B., et al. (2011) The Pathophysiology of IgA Nephropathy. Journal of the American Society of Nephrology, 22, 1795-1803. [Google Scholar] [CrossRef] [PubMed]
[10] Seikrit, C. and Pabst, O. (2021) The Immune Landscape of IgA Induction in the Gut. Seminars in Immunopathology, 43, 627-637. [Google Scholar] [CrossRef] [PubMed]
[11] Gesualdo, L., Di Leo, V. and Coppo, R. (2021) The Mucosal Immune System and IgA Nephropathy. Seminars in Immunopathology, 43, 657-668. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, X., Yan, Z., Pan, Q., Zhang, C., Chen, Y., Liang, X., et al. (2024) Bibliometric Analysis of Mucosal Immunity in IgA Nephropathy from 1990 to 2022. Immunity, Inflammation and Disease, 12, e1156. [Google Scholar] [CrossRef] [PubMed]
[13] 陈琪, 周静威, 陈振杰, 等. 基于伏邪温病理论探讨IgA肾病中的黏膜免疫机制[J]. 中医学报, 2022, 37(12): 2525-2529.
[14] Kiryluk, K., Li, Y., Scolari, F., Sanna-Cherchi, S., Choi, M., Verbitsky, M., et al. (2014) Discovery of New Risk Loci for IgA Nephropathy Implicates Genes Involved in Immunity against Intestinal Pathogens. Nature Genetics, 46, 1187-1196. [Google Scholar] [CrossRef] [PubMed]
[15] Floege, J. and Feehally, J. (2015) The Mucosa-Kidney Axis in IgA Nephropathy. Nature Reviews Nephrology, 12, 147-156. [Google Scholar] [CrossRef] [PubMed]
[16] 姜健, 王娴娴, 沈沛成, 等. IgA肾病患者黏膜免疫系统情况的临床调查[J]. 大连医科大学学报, 2016, 38(6): 558-561.
[17] Harabuchi, Y. and Takahara, M. (2019) Recent Advances in the Immunological Understanding of Association between Tonsil and Immunoglobulin a Nephropathy as a Tonsil‐Induced Autoimmune/Inflammatory Syndrome. Immunity, Inflammation and Disease, 7, 86-92. [Google Scholar] [CrossRef] [PubMed]
[18] 张沥涟, 席晓荣, 肖瑾, 等. 基于肺与大肠相表里探讨肺肠共治[J]. 光明中医, 2023, 38(17): 3317-3320.
[19] 李雪, 陈静, 马放, 等. 占永立教授从咽论治IgA肾病的理论与实践探析[J]. 世界中医药, 2019, 14(4): 1002-1005, 1010.
[20] 刘艳华, 任喜洁, 王健, 等. 任继学应用喉肾相关理论诊治慢性肾风经验[J]. 中医杂志, 2015, 56(4): 283-285.
[21] Dickson, R.P., Singer, B.H., Newstead, M.W., Falkowski, N.R., Erb-Downward, J.R., Standiford, T.J., et al. (2016) Enrichment of the Lung Microbiome with Gut Bacteria in Sepsis and the Acute Respiratory Distress Syndrome. Nature Microbiology, 1, Article No. 16113. [Google Scholar] [CrossRef] [PubMed]
[22] He, Y., Wen, Q., Yao, F., Xu, D., Huang, Y. and Wang, J. (2016) Gut-Lung Axis: The Microbial Contributions and Clinical Implications. Critical Reviews in Microbiology, 43, 81-95. [Google Scholar] [CrossRef] [PubMed]
[23] Wypych, T.P., Wickramasinghe, L.C. and Marsland, B.J. (2019) The Influence of the Microbiome on Respiratory Health. Nature Immunology, 20, 1279-1290. [Google Scholar] [CrossRef] [PubMed]
[24] Chakradhar, S. (2017) A Curious Connection: Teasing Apart the Link between Gut Microbes and Lung Disease. Nature Medicine, 23, 402-404. [Google Scholar] [CrossRef] [PubMed]
[25] Kiryluk, K., Li, Y., Sanna-Cherchi, S., Rohanizadegan, M., Suzuki, H., Eitner, F., et al. (2012) Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genetics, 8, e1002765. [Google Scholar] [CrossRef] [PubMed]
[26] Meijers, B.K.I. and Evenepoel, P. (2011) The Gut-Kidney Axis: Indoxyl Sulfate, P-Cresyl Sulfate and CKD Progression. Nephrology Dialysis Transplantation, 26, 759-761. [Google Scholar] [CrossRef] [PubMed]
[27] 刘声, 李立华, 等. “肺与大肠相表里”的组织细胞学基础研究[J]. 中华中医药杂志, 2012, 27(4): 1167-1170.
[28] 刘春艳, 柴艺汇, 等. 基于“肠道菌群-SCFAs-Th17/Treg细胞轴”探讨果上叶对COPD的影响[J]. 湖北民族大学学报(医学版), 2023, 40(2): 65-69.
[29] 孔靖玮, 吴珺, 等. CD4~+T细胞迁移在哮喘小鼠“肺合大肠”的初探[J]. 中国免疫学杂志, 2021, 37(4): 400-404+409.
[30] 季幸姝, 侯丽颖. 应用蛋白质组学探讨中医“肺与大肠相表里”理论[J]. 中医杂志, 2008, 49(12): 1065-1067.
[31] Huang, Y., Mao, K., Chen, X., Sun, M., Kawabe, T., Li, W., et al. (2018) S1P-Dependent Interorgan Trafficking of Group 2 Innate Lymphoid Cells Supports Host Defense. Science, 359, 114-119. [Google Scholar] [CrossRef] [PubMed]
[32] 郑秀丽, 杨宇, 郑旭锐, 等. 从肺肠菌群变化的相关性探讨“肺与大肠相表里” [J]. 中华中医药杂志, 2013, 28(8): 2294-2296.
[33] Budden, K.F., Gellatly, S.L., Wood, D.L.A., Cooper, M.A., Morrison, M., Hugenholtz, P., et al. (2016) Emerging Pathogenic Links between Microbiota and the Gut-lung Axis. Nature Reviews Microbiology, 15, 55-63. [Google Scholar] [CrossRef] [PubMed]
[34] Mjösberg, J. and Rao, A. (2018) Lung Inflammation Originating in the Gut. Science, 359, 36-37. [Google Scholar] [CrossRef] [PubMed]
[35] Barratt, J., Lafayette, R.A., Rovin, B.H. and Fellström, B. (2023) Budesonide Delayed-Release Capsules to Reduce Proteinuria in Adults with Primary Immunoglobulin a Nephropathy. Expert Review of Clinical Immunology, 19, 699-710. [Google Scholar] [CrossRef] [PubMed]
[36] Coppo, R. (2017) The Gut-Kidney Axis in IgA Nephropathy: Role of Microbiota and Diet on Genetic Predisposition. Pediatric Nephrology, 33, 53-61. [Google Scholar] [CrossRef] [PubMed]
[37] 李春雷. 肺主卫气与皮肤黏膜免疫的相关实验研究[C]//中华中医药学会中药实验药理分会第八届学术会议论文汇编. 济南: 山东中医药大学教学实验中心, 2009: 127.
[38] 张芮, 林燕. 曹式丽教授从外感辨治IgA肾病经验[J]. 西部中医药, 2021, 34(2): 52-55.
[39] 陆素琴, 刁金囡, 邹燕勤. 邹燕勤教授应用咽肾相关理论治疗慢性肾炎的经验[J]. 中国中医药现代远程教育, 2020, 18(9): 45-47.
[40] 高坤, 张颖煜, 等. 国医大师邹燕勤从咽论治IgA肾病临证撷菁[J]. 江苏中医药, 2020, 52(9): 14-16.
[41] 孙丽燕. 清热凉血化瘀汤联合点刺放血治疗IgA肾病瘀热互结咽喉证的临床观察[J]. 河北中医, 2019, 41(8): 1146-1151.
[42] 樊然然, 刘玉宁. 刘玉宁教授运用中医辨病论治IgA肾病的临床疗效观察及用药规律分析[J]. 中国中西医结合肾病杂志, 2020, 21(11): 970-972.
[43] 陈小娟, 王刚, 等. 咽肾关系理论在宣清和化方治疗IgA肾病中的应用[J]. 世界中医药, 2023, 18(18): 2635-2639.
[44] 聂莉芳, 余仁欢, 于大君. 15年来我国IgA肾病中医证候学研究分析[J]. 上海中医药杂志, 2004(2): 59-61.
[45] 聂莉芳, 余仁欢, 于大君, 等. 益气滋肾颗粒控制IgA肾病血尿的多中心临床疗效评价[J]. 中国中西医结合肾病杂志, 2006, 7(4): 215-218.
[46] 余仁欢, 聂莉芳, 徐建龙, 等. 益气滋肾颗粒干预IgA肾病蛋白尿的临床疗效评价[J]. 中国中西医结合肾病杂志, 2010, 11(8): 721-722.
[47] 陈其艳, 傅超美, 罗锐锋, 等. 大黄及其蒽醌对自身免疫性疾病治疗的研究进展[J]. 中国中药杂志, 2021, 46(1): 15-23.
[48] 涂玥, 孙伟, 万毅刚, 等. 大黄附子汤调控JNK/Bcl-2信号通路而改善尿酸性肾病肾小管间质损伤的机制[J]. 中华中医药杂志, 2013, 28(5): 1351-1353.
[49] 张程亮, 任秀华, 等. 柴胡黄芩药对的基础研究探析[J]. 世界科学技术-中医药现代化, 2019, 21(1): 33-37.
[50] Park, J.I., Kim, T., Oh, B., Cho, H., Kim, J.E., Yoo, S.H., et al. (2020) Comparative Analysis of the Tonsillar Microbiota in IgA Nephropathy and Other Glomerular Diseases. Scientific Reports, 10, Article No. 16206. [Google Scholar] [CrossRef] [PubMed]
[51] Xie, Y., Chen, X., Nishi, S., Narita, I. and Gejyo, F. (2004) Relationship between Tonsils and IgA Nephropathy as Well as Indications of Tonsillectomy. Kidney International, 65, 1135-1144. [Google Scholar] [CrossRef] [PubMed]
[52] Duan, J., Liu, D., Duan, G. and Liu, Z. (2016) Long-Term Efficacy of Tonsillectomy as a Treatment in Patients with IgA Nephropathy: A Meta-Analysis. International Urology and Nephrology, 49, 103-112. [Google Scholar] [CrossRef] [PubMed]
[53] Rodrigues, J.C., Haas, M. and Reich, H.N. (2017) IgA Nephropathy. Clinical Journal of the American Society of Nephrology, 12, 677-686. [Google Scholar] [CrossRef] [PubMed]
[54] Fellström, B.C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J.W., et al. (2017) Targeted-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial. The Lancet, 389, 2117-2127. [Google Scholar] [CrossRef] [PubMed]
[55] Smerud, H.K., Barany, P., Lindstrom, K., Fernstrom, A., Sandell, A., Pahlsson, P., et al. (2011) New Treatment for IgA Nephropathy: Enteric Budesonide Targeted to the Ileocecal Region Ameliorates Proteinuria. Nephrology Dialysis Transplantation, 26, 3237-3242. [Google Scholar] [CrossRef] [PubMed]
[56] Takahara, M., Nagato, T., Nozaki, Y., Kumai, T., Katada, A., Hayashi, T., et al. (2019) A Proliferation-Inducing Ligand (APRIL) Induced Hyper-Production of IgA from Tonsillar Mononuclear Cells in Patients with IgA Nephropathy. Cellular Immunology, 341, Article ID: 103925. [Google Scholar] [CrossRef] [PubMed]
[57] 王畅, 王睿智. IgA肾病靶向治疗新进展[J]. 肾脏病与透析肾移植杂志, 2022, 31(3): 271-276.

为你推荐